二十碳五烯酸乙酯降低高甘油三酯血症患者心血管风险
REDUCE-IT为多中心、随机、双盲、安慰剂对照试验,纳入已确诊心血管病或糖尿病伴其他危险因素、正在接受他汀治疗、空腹甘油三酯135–499 mg/dL(1.52–5.63 mmol/L)且LDL-C 41–100 mg/dL(1.06–2.59 mmol/L)的患者8179例,随机接受二十碳五烯酸乙酯2 g每日两次(日总剂量4 g)或安慰剂,中位随访4.9年。主要终点(心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或不稳定心绞痛复合终点)发生率17.2% vs 22.0%(HR 0.75;95%CI 0.68–0.83;P<0.001)。关键次要终点11.2% vs 14.8%(HR 0.74;95%CI 0.65–0.83;P<0.001),心血管死亡4.3% vs 5.2%(HR 0.80;95%CI 0.66–0.98;P=0.03)。二十碳五烯酸乙酯组因心房颤动或心房扑动住院比例更高(3.1% vs 2.1%,P=0.004),严重出血事件2.7% vs 2.1%(P=0.06)。
要点
- 适用人群:已确诊心血管病或糖尿病伴其他危险因素、正在接受他汀治疗、空腹甘油三酯135–499 mg/dL且LDL-C 41–100 mg/dL者。
- 二十碳五烯酸乙酯2 g每日两次(日总剂量4 g)使主要复合终点从22.0%降至17.2%(HR 0.75;95%CI 0.68–0.83;P<0.001)。
- 关键次要终点(心血管死亡、非致死性心肌梗死、非致死性卒中)11.2% vs 14.8%(HR 0.74;95%CI 0.65–0.83;P<0.001)。
- 心血管死亡4.3% vs 5.2%(HR 0.80;95%CI 0.66–0.98;P=0.03)。
- 因心房颤动或心房扑动住院3.1% vs 2.1%(P=0.004);严重出血事件2.7% vs 2.1%(P=0.06)。
适用人群与场景
- 已确诊心血管病,或糖尿病伴其他危险因素,且正在接受他汀治疗的患者
- 空腹甘油三酯135–499 mg/dL(1.52–5.63 mmol/L)且LDL-C 41–100 mg/dL(1.06–2.59 mmol/L)
- 8179例中70.7%为心血管事件二级预防
诊断标准与关键阈值
- 空腹甘油三酯135–499 mg/dL(1.52–5.63 mmol/L)
- LDL-C 41–100 mg/dL(1.06–2.59 mmol/L)
处置流程与药物剂量
- 随机接受二十碳五烯酸乙酯2 g每日两次(日总剂量4 g)或安慰剂,中位随访4.9年
研究设计与关键结果
- 多中心、随机、双盲、安慰剂对照试验,8179例,中位随访4.9年
- 主要终点(心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或不稳定心绞痛)17.2% vs 22.0%(HR 0.75;95%CI 0.68–0.83;P<0.001)
- 关键次要终点(心血管死亡、非致死性心肌梗死、非致死性卒中)11.2% vs 14.8%(HR 0.74;95%CI 0.65–0.83;P<0.001)
- 心血管死亡4.3% vs 5.2%(HR 0.80;95%CI 0.66–0.98;P=0.03)
- 因心房颤动或心房扑动住院3.1% vs 2.1%(P=0.004)
- 严重出血事件2.7% vs 2.1%(P=0.06)
证据类型、等级与局限
- 证据类型:多中心随机双盲安慰剂对照试验(REDUCE-IT,NCT01492361)
- 局限:原文未报告局限性
对床旁实践的改变
- 作者结论:在接受他汀治疗但甘油三酯仍升高的患者中,二十碳五烯酸乙酯2 g每日两次较安慰剂显著降低缺血事件(包括心血管死亡)风险
- 二十碳五烯酸乙酯组因心房颤动或心房扑动住院比例高于安慰剂组(3.1% vs 2.1%,P=0.004)
指南或共识出处
- REDUCE-IT试验(ClinicalTrials.gov NCT01492361),由Amarin Pharma资助
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events.
METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).
CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
参考来源
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2018. PMID: 30415628. doi:10.1056/NEJMoa1812792
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。